Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005

NEWS EXPRESS	OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:36:30 ON 07 JAN 2005

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:36:44 ON 07 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JAN 2005 HIGHEST RN 808732-83-4
DICTIONARY FILE UPDATES: 5 JAN 2005 HIGHEST RN 808732-83-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10613414.str



chain nodes :
17 18 19 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
chain bonds :

1-13 4-11 7-17 9-18 18-19
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 12-13 12-16 13-14
14-15 15-16
exact/norm bonds :
1-13 4-11 7-8 7-11 7-17 8-9 9-10 9-18 10-11 12-13 12-16 13-14 14-15
15-16 18-19
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 7 : 12 :

G1:O,S,N,CH2,CH

G2:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
21:CLASS 24:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,N,CH2,CH
G2 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 10:37:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 53 TO ITERATE

100.0% PROCESSED 53 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 624 TO 1496
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 10:37:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1184 TO ITERATE

100.0% PROCESSED 1184 ITERATIONS 27 ANSWERS
SEARCH TIME: 00.00.01

L3 27 SEA SSS FUL L1

=> FIL CAPLUS
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.76	161.97

FILE 'CAPLUS' ENTERED AT 10:37:57 ON 07 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jan 2005 VOL 142 ISS 3
FILE LAST UPDATED: 6 Jan 2005 (20050106/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 6 L3

=> d l4 ibib abs hitstr tot

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:430626 CAPLUS
DOCUMENT NUMBER: 141:7113
TITLE: Preparation of novel heterocyclic compounds having antibacterial activity
INVENTOR(S): Selvakumar, Natesan; Das, Jagattaran; Trehan, Sanjay; Iqbal, Javed; Kumar, Magadi Sitaram; Rajagopalan, Ramanujam; Rao, Mamidi Naga Venkata Srinivasa
PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories Inc.
SOURCE: U.S. Pat. Appl. Publ., 100 pp., Cont.-in-part of U.S.

Pat. Appl. 2003 65,175.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004102494	A1	20040527	US 2003-613414	20030703
US 2003065175	A1	20030403	US 2001-32392	20011221
US 2004059120	A1	20040325	US 2003-632950	20030801

PRIORITY APPLN. INFO.: IN 2000-MA1124 A 20001226
IN 2001-MA15 A 20010115
US 2001-32392 A2 20011221

OTHER SOURCE(S): MARPAT 141:7113

GI



I



II

AB The title compds. [I; R1 = NHR4 (wherein R4 = thioacyl, C(S)cycloalkoxy, C(S)aryloxy, etc.); R2, R3 = H, halo, alkyl, etc.; Y1 = O, S; Y2, Y3 = H, halo, CN, etc.; Z = O, S, CH, CH2, (un)substituted NH], useful for inhibiting the growth of bacteria in a subject having a bacterial infection (MIC values given for some of the compds. I), were prepared E.g., a multi-step synthesis of II was given. The pharmaceutical composition comprising the compound I is claimed.

IT **693787-27-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of novel 4-(4-oxoimidazol-1-yl)phenyl substituted oxazolidinones having antibacterial activity)

RN 693787-27-8 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3,5-difluoro-4-(4-oxo-1-imidazolidinyl)phenyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **439903-85-2P 693787-28-9P 693787-29-0P**
693787-36-9P 693787-37-0P 693787-38-1P
693787-39-2P 693787-40-5P 693787-43-8P
693787-45-0P 693787-52-9P 693787-53-0P
693787-54-1P 693787-58-5P 693787-59-6P
693787-61-0P 693787-62-1P 693787-63-2P
693787-78-9P 693787-79-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel 4-(4-oxoimidazol-1-yl)phenyl substituted oxazolidinones having antibacterial activity)

RN 439903-85-2 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(4-oxo-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693787-28-9 CAPLUS

CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3,5-difluoro-4-(4-oxo-1-imidazolidinyl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693787-29-0 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3,5-difluoro-4-(4-oxo-1-imidazolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 693787-36-9 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3-fluoro-4-(4-thioxo-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693787-37-0 CAPLUS
CN Ethanethioamide, N-[[(5S)-3-[3,5-difluoro-4-(4-oxo-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693787-38-1 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[3,5-difluoro-4-(4-oxo-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693787-39-2 CAPLUS
CN Carbamothioic acid, [[(5R)-3-[3,5-difluoro-4-(4-oxo-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693787-40-5 CAPLUS
CN Carbamothioic acid, [[3-[3,5-difluoro-4-(4-oxo-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)



RN 693787-43-8 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(4-thioxo-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693787-45-0 CAPLUS
CN Carbamothioic acid, [[(5S)-2-oxo-3-[4-(4-oxo-1-imidazolidinyl)phenyl]-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693787-52-9 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[3,5-difluoro-4-(4-oxo-1-

imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693787-53-0 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[3,5-difluoro-4-(4-oxo-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693787-54-1 CAPLUS
CN Carbamothioic acid, [[(5S)-3-[3,5-difluoro-4-(4-oxo-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-(1-methylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693787-58-5 CAPLUS
CN Carbamothioic acid, [[(5R)-3-[3,5-difluoro-4-(4-oxo-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693787-59-6 CAPLUS
CN Carbamothioic acid, [[(5R)-3-[3,5-difluoro-4-(4-oxo-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693787-61-0 CAPLUS
CN Carbamothioic acid, [[3-[3,5-difluoro-4-(4-oxo-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-propyl ester (9CI) (CA INDEX NAME)



RN 693787-62-1 CAPLUS
CN Carbamothioic acid, [[3-[3,5-difluoro-4-(4-oxo-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-ethyl ester (9CI) (CA INDEX NAME)



RN 693787-63-2 CAPLUS
CN Thiourea, N-[[(5S)-3-[3,5-difluoró-4-(4-oxo-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-N'-2-pyridinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693787-78-9 CAPLUS
CN Ethanethioamide, N-[[(5R)-3-[3,5-difluoro-4-(4-oxo-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 693787-79-0 CAPLUS
CN Carbamic acid, [[(5R)-3-[3,5-difluoro-4-(4-oxo-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:333714 CAPLUS
DOCUMENT NUMBER: 140:357327
TITLE: Preparation of bicyclic[3.1.0]oxazolidinones and related compounds as antibacterial agents
INVENTOR(S): Gordeev, Mikhail Fedor; Renslo, Adam; Patel, Dinesh Vinoobhai
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033451	A1	20040422	WO 2003-US28560	20031003

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,

OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004127530 A1 20040701 US 2003-677451 20031002
PRIORITY APPLN. INFO.: US 2002-417735P P 20021009
OTHER SOURCE(S): MARPAT 140:357327
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R2, R3 = H, F; R4, R5 = H, Cl, F, etc.; R6, R7 = H, F, OH, etc.; R8 = H, F, OH, etc.; A = 5-methyl-2-oxazolidinonyl, 4,5-dihydro-5-Me-oxazolyl, dihydro-5-Me-2(3H)-furanonyl, etc.; B = (CH2)n; n = 0-1; X = N, CH; Y = N, O, S; Z = NHCOR1, NHCSR1, CONHR1, etc.; R1 = H, NH2, NH-alkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, condensation of CBZ-protected benzenamine II, e.g., prepared from benzyl 3-pyrroline-1-carboxylate in 5-steps, and (S)-acetic acid 2-acetylamino-1-chloromethylethyl ester afforded oxazolidinone III in 62% yield. In S. aureus Min. Inhibitory Concentration (MIC) growth studies, 6-examples of compds. I exhibited MIC values ranging from 1-8 μg/mL, i.e., the MIC value of oxazolidinone III was 1 μg/mL. Compds. I are claimed useful for the treatment of skin and eye infections.

IT **681425-61-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bicyclic[3.1.0]oxazolidinones and related compds. as antibacterial agents)

RN 681425-61-6 CAPLUS
CN Acetamide, N-[[(5S)-3-[4-(3-azido-4-hydroxy-1-pyrrolidinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:5775 CAPLUS
DOCUMENT NUMBER: 138:89797

TITLE: Preparation of substituted oxazolidinones for combinational therapy in the treatment and/or prophylaxis of thromboembolic diseases

INVENTOR(S): Straub, Alexander; Lampe, Thomas; Pernerstorfer, Josef; Perzborn, Elisabeth; Pohlmann, Jens; Roehrig, Susanne; Schlemmer, Karl-Heinz

PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000256	A1	20030~~103~~	WO 2002-EP6237	20020607
WO 2003000256	C2	20030206		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10129725	A1	20030102	DE 2001-10129725	20010620
EE 200400020	A	20040415	EE 2004-20	20020607
EP 1411932	A1	20040428	EP 2002-738154	20020607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002010941	A	20040608	BR 2002-10941	20020607
JP 2004534083	T2	20041111	JP 2003-506901	20020607
US 2004242660	A1	20041202	US 2004-481297	20040628

PRIORITY APPLN. INFO.: DE 2001-10129725 A 20010620
WO 2002-EP6237 W 20020607

OTHER SOURCE(S): MARPAT 138:89797

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to combinations of (A) oxazolidinones I [R1 = 5-X-2-thienyl (X = Cl, Br, Me, CF3); R2 = DA; A = phenylene; D = 5- or 6-membered heterocyclic ring containing S, N or O; R4 - R8 = H], or their pharmaceutically acceptable salts, hydrates, prodrugs or their mixts. and (B) other pharmaceutically active ingredients; to a method for producing said combinations; and to the use thereof as medicaments, in particular for the treatment and/or prophylaxis of thrombo-embolic diseases. Thus, the claimed oxazolone II was prepared from epoxide III via epoxide ring opening with aniline derivative IV, cyclization with carbonyldiimidazole, and N-acylation with 5-chlorothiophene-2-sulfonyl chloride. II was tested for antithrombotic activity in the arteriovenous shunt model (Rat) after [ED50 = 3 mg/kg (p.o.); IC50 = 0.7 nM]; II had a synergistic effect when used in combination with clopidogrel.

IT **482306-69-4P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and pharmacol. activity of; preparation of substituted oxazolidinones for combinational therapy in the treatment and/or prophylaxis of thromboembolic diseases)

RN 482306-69-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[[3-[3-fluoro-4-(3-hydroxy-1-pyrrolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:504766 CAPLUS
DOCUMENT NUMBER: 137:78944
TITLE: Preparation of aryloxazolones as antibacterials.
INVENTOR(S): Natesan, Selvakumar; Das, Jagattaran; Iqbal, Javed; Magadi, Sitaram Kumar; Mamidi, Naga Venkata Srinivasa Rao; Ramanujam, Rajagopalan; Sundarababu, Baskaran; Lohray, Braj Bhushan
PATENT ASSIGNEE(S): Dr. Reddy's Research Foundation, India; Dr. Reddy's Laboratoties Ltd.
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051819	A2	20020704	WO 2001-IN227	20011226
WO 2002051819	A3	20021205		
WO 2002051819	C2	20030807		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2433138	AA	20020704	CA 2001-2433138	20011226
EP 1345913	A2	20030924	EP 2001-995805	20011226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300254	A	20031215	EE 2003-254	20011226
BR 2001016571	A	20040302	BR 2001-16571	20011226

JP 2004525876	T2	20040826	JP 2002-552914		20011226
NO 2003002926	A	20030825	NO 2003-2926		20030625
PRIORITY APPLN. INFO.:			IN 2000-MA1124	A	20001226
			IN 2001-MA15	A	20010115
			WO 2001-IN227	W	20011226

OTHER SOURCE(S): MARPAT 137:78944
GI



I



II

AB Title compds. [I; R1 = halo, N3, SCN, SH, OR4, NHR4, N(R4)2; R4 = H, (substituted) acyl, thioacyl, alkoxycarbonyl, cycloalkoxythiocarbonyl, alkenyloxycarbonyl, alkenylcarbonyl, aryloxycarbonyl, alkoxythiocarbonyl, alkenyloxythiocarbonyl, aryloxythiocarbonyl, COCOA, COCOAr, COCOAlk, COCOArO, CS2A, CSNH2, CSNHA, CSNA2, CSNHAk, CSCOAlk, CSCOArO, CSO2CA, CSCSA, CSCSAr, thiomorpholinylthiocarbonyl, pyrrolidinylthiocarbonyl; A = alkyl; Ar = aryl; Alk = alkoxy; Ak = alkenyl; R2, R3 = H, halo, alkyl, haloalkyl, cyano, nitro, SRa, NRa, ORa; Ra = (substituted) alkyl, haloalkyl; Z = S, O, CH, NRb; Rb = H, (substituted) alkyl, alkenyl, cycloalkyl, alkoxy, aryl, aralkyl, aryloxy, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aryloxycarbonyl; Y1 = O, S; Y2, Y3 = H, halo, cyano, NO2, formyl, OH, amino, O, S, (substituted) alkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, carboxyalkyl, alkylsulfonyl, alkylcarbonylaminoalkyl, arylcarbonylaminoalkyl, alkylcarbonyloxyalkyl, aminoalkyl, monoalkylamino, dialkylamino, arylamino, alkoxy, aryl, aryloxy, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl heterocycloalkyl; adjacent Y2Y3 form a (substituted) 5-6 membered aromatic or nonarom. cyclic structure, optionally containing 1-2 heteroatoms], were prepared Thus, title compound (II) (general preparation given) showed a min. inhibitory concentration of 0.25 μg/mL against
Staphylococcus aureus 019 MRSA.

IT **439903-85-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryloxazolones as antibacterials)

RN 439903-85-2 CAPLUS

CN Carbamothioic acid, [[(5S)-3-[3-fluoro-4-(4-oxo-1-imidazolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, O-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:324112 CAPLUS
DOCUMENT NUMBER: 126:293348
TITLE: Preparation of 5-acylaminomethyl-3-(N-oxidoheterocyclyl)phenyl-2-oxazolidinones as antibacterial prodrugs
INVENTOR(S): Gadwood, Robert C.; Kamdar, Bharat V.
PATENT ASSIGNEE(S): Upjohn Co., USA; Gadwood, Robert C.; Kamdar, Bharat V.
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9710223	A1	19970320	WO 1996-US14135	19960909
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI				
AU 9669640	A1	19970401	AU 1996-69640	19960909
JP 11512429	T2	19991026	JP 1996-511993	19960909
EP 1019385	A1	20000719	EP 1996-930676	19960909
EP 1019385	B1	20040114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
US 6277985	B1	20010821	US 1996-709998	19960909
AT 257829	E	20040115	AT 1996-930676	19960909
PT 1019385	T	20040630	PT 1996-930676	19960909
ES 2214546	T3	20040916	ES 1996-930676	19960909
US 2001051722	A1	20011213	US 2001-894019	20010628
US 6512112	B2	20030128		
US 2002107402	A1	20020808	US 2001-988078	20010628
US 6441188	B2	20020827		
US 2002120152	A1	20020829	US 2001-988079	20010628
US 6515135	B2	20030204		
US 2002177707	A1	20021128	US 2001-988076	20010628

US 6525193	B2	20030225			
US 6518427	B1	20030211	US 2001-988077		20010628
PRIORITY APPLN. INFO.:			US 1995-3838P	P	19950915
			US 1996-709998	A3	19960909
			WO 1996-US14135	W	19960909

OTHER SOURCE(S): MARPAT 126:293348
GI



I

AB Title compds. [I; R = N-attached-N-oxido-hetero(bi)cyclyl; R1 = CHO, Ac, CO2Me, etc.; R2,R3 = H, F, Cl] were prepared Thus, I (R = 4-hydroxyacetyl-1-piperazinyl, R1 = Ac, R2 = F, R3 = H) was oxidized to give I (R = 4-hydroxyacetyl-1-oxido-1-piperazinyl, R1 = Ac, R2 = F, R3 = H). Data for biol. activity of I were given.

IT **189038-52-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 5-acylaminomethyl-3-(N-oxidoheterocyclyl)phenyl-2-oxazolidinones as antibacterial prodrugs)

RN 189038-52-6 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-(3-hydroxy-1-oxido-1-pyrrolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-, [1(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	1996:476651 CAPLUS
DOCUMENT NUMBER:	125:142706
TITLE:	Phenyloxazolidinone antimicrobials
INVENTOR(S):	Hutchinson, Douglas K.; Barbachyn, Michael R.; Taniguchi, Mikio; Munesada, Kiyotaka; Yamada, Hiroyoshi; Brickner, Steven J.
PATENT ASSIGNEE(S):	Upjohn Co., USA
SOURCE:	PCT Int. Appl., 88 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9613502	A1	19960509	WO 1995-US10992	19950912
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2200433	AA	19960509	CA 1995-2200433	19950912
AU 9536254	A1	19960523	AU 1995-36254	19950912
AU 694271	B2	19980716		
EP 788498	A1	19970813	EP 1995-933718	19950912
EP 788498	B1	20010816		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1162312	A	19971015	CN 1995-195908	19950912
CN 1068325	B	20010711		
HU 77602	A2	19980629	HU 1997-2015	19950912
BR 9509136	A	19980721	BR 1995-9136	19950912
JP 10508017	T2	19980804	JP 1995-514540	19950912
RU 2134692	C1	19990820	RU 1997-108157	19950912
AT 204277	E	20010915	AT 1995-933718	19950912
ES 2162941	T3	20020116	ES 1995-933718	19950912
PT 788498	T	20020228	PT 1995-933718	19950912
PL 183512	B1	20020628	PL 1995-319873	19950912
SK 282869	B6	20030109	SK 1997-494	19950912
CZ 291847	B6	20030618	CZ 1997-1217	19950912
US 5883093	A	19990316	US 1997-913190	19970423
FI 9701774	A	19970425	FI 1997-1774	19970425
NO 9701946	A	19970625	NO 1997-1946	19970425
PRIORITY APPLN. INFO.:			US 1994-329717 A2	19941026
			WO 1995-US10992 W	19950912

OTHER SOURCE(S): MARPAT 125:142706
GI



I



II



III

AB Title compds. I [Q = certain substituted 1-azetidinyl and 1-pyrrolidinyl substituents; R1 = H, OMe, F, Cl; R2 = H, (un)substituted alkyl, cycloalkyl, (di)(alkyl)amino, alkoxy] and their pharmaceutically acceptable salts are claimed. The compds. are useful antimicrobial agents, effective against a number of human and veterinary pathogens, particularly aerobic gram-pos. bacteria, including multiply-resistant staphylococci, enterococci and streptococci, as well as anaerobic organisms such as bacteroids and clostridia species, and acid-fast bacteria such as Mycobacterium tuberculosis and other mycobacterial species. For example, 1-(diphenylmethyl)-3-azetidinol-HCl underwent N-deprotection and N-arylation with 3,4-difluoronitrobenzene (65%), O-silylation with tert-BuSiMe2Cl (74%), hydrogenation of the nitro group to an amine and N-benzyloxycarbonylation (43%), and lithiation and reaction with (R)-glycidyl butyrate (75%), to give intermediate oxazolidinylmethanol derivative II. This was subjected to O-mesylation and conversion to an azide (56%), hydrogenolysis of the azide and acetylation of the resulting amine (84%), desilylation, and oxidation of the deprotected alc. (47%), to give title compound III. The MIC values of III against Staphylococcus aureus UC 9213 and Streptococcus pneumoniae UC 9912 were 1 and 0.5 μg/mL, resp.

IT **179620-34-9P 179620-79-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; phenyloxazolidinone antimicrobials)

RN 179620-34-9 CAPLUS

CN Acetamide, N-[[3-[3-fluoro-4-(3-hydroxy-1-pyrrolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 179620-79-2 CAPLUS
CN Acetamide, N-[[3-[4-[3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-pyrrolidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



IT **179620-33-8P 179620-34-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenyloxazolidinone antimicrobials)
RN 179620-33-8 CAPLUS
CN Acetamide, N-[[3-[4-(3,4-dihydroxy-1-pyrrolidinyl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 179620-34-9 CAPLUS
CN Acetamide, N-[[3-[3-fluoro-4-(3-hydroxy-1-pyrrolidinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.09	192.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.38	-4.38

STN INTERNATIONAL LOGOFF AT 10:38:25 ON 07 JAN 2005